Florida Statutes
Fla. Stat. § 893.03 (2025)
Standards and schedules.
✓ 2025 Florida Statutes — current through the 2025 Regular Session
Find cases:
SyfertCases citing this section
FL-LEGleg.state.fl.us
JustiaFla. Statutes
CornellLII Search
CasesGoogle Scholar
893.03 Standards and schedules.—The substances enumerated in this section are controlled by this chapter. The controlled substances listed or to be listed in Schedules I, II, III, IV, and V are included by whatever official, common, usual, chemical, trade name, or class designated. The provisions of this section shall not be construed to include within any of the schedules contained in this section any excluded drugs listed within the purview of 21 C.F.R. s. 1308.22, styled “Excluded Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt Anabolic Steroid Products.”
(1) SCHEDULE I.—A substance in Schedule I has a high potential for abuse and has no currently accepted medical use in treatment in the United States and in its use under medical supervision does not meet accepted safety standards. The following substances are controlled in Schedule I:
(a) Unless specifically excepted or unless listed in another schedule, any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:
1. Acetyl-alpha-methylfentanyl.
2. Acetylmethadol.
3. Allylprodine.
4. Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM).
5. Alphamethadol.
6. Alpha-methylfentanyl (N-[1-(alpha-methyl-betaphenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine).
7. Alpha-methylthiofentanyl.
8. Alphameprodine.
9. Benzethidine.
10. Benzylfentanyl.
11. Betacetylmethadol.
12. Beta-hydroxyfentanyl.
13. Beta-hydroxy-3-methylfentanyl.
14. Betameprodine.
15. Betamethadol.
16. Betaprodine.
17. Clonitazene.
18. Dextromoramide.
19. Diampromide.
20. Diethylthiambutene.
21. Difenoxin.
22. Dimenoxadol.
23. Dimepheptanol.
24. Dimethylthiambutene.
25. Dioxaphetyl butyrate.
26. Dipipanone.
27. Ethylmethylthiambutene.
28. Etonitazene.
29. Etoxeridine.
30. Flunitrazepam.
31. Furethidine.
32. Hydroxypethidine.
33. Ketobemidone.
34. Levomoramide.
35. Levophenacylmorphan.
36. Desmethylprodine (1-Methyl-4-Phenyl-4-Propionoxypiperidine).
37. 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide).
38. 3-Methylthiofentanyl.
39. Morpheridine.
40. Noracymethadol.
41. Norlevorphanol.
42. Normethadone.
43. Norpipanone.
44. Para-Fluorofentanyl.
45. Phenadoxone.
46. Phenampromide.
47. Phenomorphan.
48. Phenoperidine.
49. PEPAP (1-(2-Phenylethyl)-4-Phenyl-4-Acetyloxypiperidine).
50. Piritramide.
51. Proheptazine.
52. Properidine.
53. Propiram.
54. Racemoramide.
55. Thenylfentanyl.
56. Thiofentanyl.
57. Tianeptine.
58. Tilidine.
59. Trimeperidine.
60. Acetylfentanyl.
61. Butyrylfentanyl.
62. Beta-Hydroxythiofentanyl.
63. Fentanyl derivatives. Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a 4-anilidopiperidine structure:
a. With or without substitution at the carbonyl of the aniline moiety with alkyl, alkenyl, carboalkoxy, cycloalkyl, methoxyalkyl, cyanoalkyl, or aryl groups, or furanyl, dihydrofuranyl, benzyl moiety, or rings containing heteroatoms sulfur, oxygen, or nitrogen;
b. With or without substitution at the piperidine amino moiety with a phenethyl, benzyl, alkylaryl (including heteroaromatics), alkyltetrazolyl ring, or an alkyl or carbomethoxy group, whether or not further substituted in the ring or group;
c. With or without substitution or addition to the piperdine ring to any extent with one or more methyl, carbomethoxy, methoxy, methoxymethyl, aryl, allyl, or ester groups;
d. With or without substitution of one or more hydrogen atoms for halogens, or methyl, alkyl, or methoxy groups, in the aromatic ring of the anilide moiety;
e. With or without substitution at the alpha or beta position of the piperidine ring with alkyl, hydroxyl, or methoxy groups;
f. With or without substitution of the benzene ring of the anilide moiety for an aromatic heterocycle; and
g. With or without substitution of the piperidine ring for a pyrrolidine ring, perhydroazepine ring, or azepine ring;
excluding, Alfentanil, Carfentanil, Fentanyl, and Sufentanil; including, but not limited to:
(I) Acetyl-alpha-methylfentanyl.
(II) Alpha-methylfentanyl (N-[1-(alpha-methyl-betaphenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine).
(III) Alpha-methylthiofentanyl.
(IV) Benzylfentanyl.
(V) Beta-hydroxyfentanyl.
(VI) Beta-hydroxy-3-methylfentanyl.
(VII) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide).
(VIII) 3-Methylthiofentanyl.
(IX) Para-Fluorofentanyl.
(X) Thenylfentanyl or Thienyl fentanyl.
(XI) Thiofentanyl.
(XII) Acetylfentanyl.
(XIII) Butyrylfentanyl.
(XIV) Beta-Hydroxythiofentanyl.
(XV) Lofentanil.
(XVI) Ocfentanil.
(XVII) Ohmfentanyl.
(XVIII) Benzodioxolefentanyl.
(XIX) Furanyl fentanyl.
(XX) Pentanoyl fentanyl.
(XXI) Cyclopentyl fentanyl.
(XXII) Isobutyryl fentanyl.
(XXIII) Remifentanil.
64. Nitazene derivatives. Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a benzimidazole ring with an ethylamine substitution at the 1-position and a benzyl ring substitution at the 2-position structure:
a. With or without substitution on the benzimidazole ring with alkyl, alkoxy, carboalkoxy, amino, nitro, or aryl groups, or halogens;
b. With or without substitution at the ethylamine amino moiety with alkyl, dialkyl, acetyl, or benzyl groups, whether or not further substituted in the ring system;
c. With or without inclusion of the ethylamine amino moiety in a cyclic structure;
d. With or without substitution of the benzyl ring; or
e. With or without replacement of the benzyl ring with an aromatic ring, including, but not limited to:
(I) Butonitazene.
(II) Clonitazene.
(III) Etodesnitazene.
(IV) Etonitazene.
(V) Flunitazene.
(VI) Isotodesnitazene.
(VII) Isotonitazene.
(VIII) Metodesnitazene.
(IX) Metonitazene.
(X) Nitazene.
(XI) N-Desethyl Etonitazene.
(XII) N-Desethyl Isotonitazene.
(XIII) N-Piperidino Etonitazene.
(XIV) N-Pyrrolidino Etonitazene.
(XV) Protonitazene.
(b) Unless specifically excepted or unless listed in another schedule, any of the following substances, their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
1. Acetorphine.
2. Acetyldihydrocodeine.
3. Benzylmorphine.
4. Codeine methylbromide.
5. Codeine-N-Oxide.
6. Cyprenorphine.
7. Desomorphine.
8. Dihydromorphine.
9. Drotebanol.
10. Etorphine (except hydrochloride salt).
11. Heroin.
12. Hydromorphinol.
13. Methyldesorphine.
14. Methyldihydromorphine.
15. Monoacetylmorphine.
16. Morphine methylbromide.
17. Morphine methylsulfonate.
18. Morphine-N-Oxide.
19. Myrophine.
20. Nicocodine.
21. Nicomorphine.
22. Normorphine.
23. Pholcodine.
24. Thebacon.
(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of their salts, isomers, including optical, positional, or geometric isomers, homologues, nitrogen-heterocyclic analogs, esters, ethers, and salts of isomers, homologues, nitrogen-heterocyclic analogs, esters, or ethers, if the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation or class description:
1. Alpha-Ethyltryptamine.
2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-oxazoline).
3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
6. Bufotenine.
7. Cannabis.
8. Cathinone.
9. DET (Diethyltryptamine).
10. 2,5-Dimethoxyamphetamine.
11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
12. DMT (Dimethyltryptamine).
13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog of phencyclidine).
14. JB-318 (N-Ethyl-3-piperidyl benzilate).
15. N-Ethylamphetamine.
16. Fenethylline.
17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
18. Ibogaine.
19. LSD (Lysergic acid diethylamide).
20. Mescaline.
21. Methcathinone.
22. 5-Methoxy-3,4-methylenedioxyamphetamine.
23. PMA (4-Methoxyamphetamine).
24. PMMA (4-Methoxymethamphetamine).
25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
27. MDA (3,4-Methylenedioxyamphetamine).
28. JB-336 (N-Methyl-3-piperidyl benzilate).
29. N,N-Dimethylamphetamine.
30. Parahexyl.
31. Peyote.
32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine analog of phencyclidine).
33. Psilocybin.
34. Psilocyn.
35. Salvia divinorum, except for any drug product approved by the United States Food and Drug Administration which contains Salvia divinorum or its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
36. Salvinorin A, except for any drug product approved by the United States Food and Drug Administration which contains Salvinorin A or its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
37. Xylazine.
38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene analog of phencyclidine).
39. 3,4,5-Trimethoxyamphetamine.
40. Methylone (3,4-Methylenedioxymethcathinone).
41. MDPV (3,4-Methylenedioxypyrovalerone).
42. Methylmethcathinone.
43. Methoxymethcathinone.
44. Fluoromethcathinone.
45. Methylethcathinone.
46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol) and its dimethyloctyl (C8) homologue.
47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole).
51. BZP (Benzylpiperazine).
52. Fluorophenylpiperazine.
53. Methylphenylpiperazine.
54. Chlorophenylpiperazine.
55. Methoxyphenylpiperazine.
56. DBZP (1,4-Dibenzylpiperazine).
57. TFMPP (Trifluoromethylphenylpiperazine).
58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-Methylenedioxy-N-methylbutanamine).
59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
60. 5-Hydroxy-N-methyltryptamine.
61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
63. Methyltryptamine.
64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
66. Tyramine (4-Hydroxyphenethylamine).
67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
68. DiPT (N,N-Diisopropyltryptamine).
69. DPT (N,N-Dipropyltryptamine).
70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
81. Butylone (3,4-Methylenedioxy-alpha-methylaminobutyrophenone).
82. Ethcathinone.
83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
84. Naphyrone (Naphthylpyrovalerone).
85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
86. 3,4-Methylenedioxy-N,N-diethylcathinone.
87. 3,4-Methylenedioxy-propiophenone.
88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
89. 3,4-Methylenedioxy-propiophenone-2-oxime.
90. 3,4-Methylenedioxy-N-acetylcathinone.
91. 3,4-Methylenedioxy-N-acetylmethcathinone.
92. 3,4-Methylenedioxy-N-acetylethcathinone.
93. Bromomethcathinone.
94. Buphedrone (alpha-Methylamino-butyrophenone).
95. Eutylone (3,4-Methylenedioxy-alpha-ethylaminobutyrophenone).
96. Dimethylcathinone.
97. Dimethylmethcathinone.
98. Pentylone (3,4-Methylenedioxy-alpha-methylaminovalerophenone).
99. MDPPP (3,4-Methylenedioxy-alpha-pyrrolidinopropiophenone).
100. MDPBP (3,4-Methylenedioxy-alpha-pyrrolidinobutyrophenone).
101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP (Benocyclidine).
104. F-MABP (Fluoromethylaminobutyrophenone).
105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
106. Et-PBP (Ethylpyrrolidinobutyrophenone).
107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
108. Me-EABP (Methylethylaminobutyrophenone).
109. Etizolam.
110. PPP (Pyrrolidinopropiophenone).
111. PBP (Pyrrolidinobutyrophenone).
112. PVP (Pyrrolidinovalerophenone) or (Pyrrolidinopentiophenone).
113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione).
133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecanamide).
135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-undecanamide).
136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-methyloctan-2-yl)phenol).
137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole).
141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone).
142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone).
143. Pentedrone (alpha-Methylaminovalerophenone).
144. Fluoroamphetamine.
145. Fluoromethamphetamine.
146. Methoxetamine.
147. Methiopropamine.
148. Methylbuphedrone (Methyl-alpha-methylaminobutyrophenone).
149. APB ((2-Aminopropyl)benzofuran).
150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
151. UR-144 (1-Pentyl-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole).
156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide).
157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)-cyclohexylcarbamate).
158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester).
159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one).
160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
161. 2C-H (2,5-Dimethoxyphenethylamine).
162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
165. MDMA (3,4-Methylenedioxymethamphetamine).
166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-carboxylate).
168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-carboxylate).
169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide).
170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).
171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).
173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(fluoropentyl)indole-3-carboxamide).
174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-carboxylate).
178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-3-carboxamide).
179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol).
183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol).
184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol).
185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol).
186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
187. MAPB ((2-Methylaminopropyl)benzofuran).
188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
190. Synthetic Cannabinoids.—Unless specifically excepted or unless listed in another schedule or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation that contains any quantity of a synthetic cannabinoid found to be in any of the following chemical class descriptions, or homologues, nitrogen-heterocyclic analogs, isomers (including optical, positional, or geometric), esters, ethers, salts, and salts of homologues, nitrogen-heterocyclic analogs, isomers, esters, or ethers, whenever the existence of such homologues, nitrogen-heterocyclic analogs, isomers, esters, ethers, salts, and salts of isomers, esters, or ethers is possible within the specific chemical class or designation. Since nomenclature of these synthetically produced cannabinoids is not internationally standardized and may continually evolve, these structures or the compounds of these structures shall be included under this subparagraph, regardless of their specific numerical designation of atomic positions covered, if it can be determined through a recognized method of scientific testing or analysis that the substance contains properties that fit within one or more of the following categories:
a. Tetrahydrocannabinols.—Any tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, the synthetic equivalents of the substances contained in the plant or in the resinous extracts of the genus Cannabis, or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity, including, but not limited to, Delta 9 tetrahydrocannabinols and their optical isomers, Delta 8 tetrahydrocannabinols and their optical isomers, Delta 6a,10a tetrahydrocannabinols and their optical isomers, or any compound containing a tetrahydrobenzo[c]chromene structure with substitution at either or both the 3-position or 9-position, with or without substitution at the 1-position with hydroxyl or alkoxy groups, including, but not limited to:
(I) Tetrahydrocannabinol.
(II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
(III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
(IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
(V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
(VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
(VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3-dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
(VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
(IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
(X) Parahexyl.
b. Naphthoylindoles, Naphthoylindazoles, Naphthoylcarbazoles, Naphthylmethylindoles, Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any compound containing a naphthoylindole, naphthoylindazole, naphthoylcarbazole, naphthylmethylindole, naphthylmethylindazole, or naphthylmethylcarbazole structure, with or without substitution on the indole, indazole, or carbazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to:
(I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
(II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-naphthoyl)indole).
(III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
(IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
(V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
(VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
(VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
(VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
(IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
(X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
(XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
(XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
(XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
(XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole).
(XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
(XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
(XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-naphthoyl)indole).
(XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
(XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
(XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
(XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
(XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-naphthylmethyl]indole).
(XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-naphthoyl)indole).
(XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-naphthoyl)indole).
(XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole).
(XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
(XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
(XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
(XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
(XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
(XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-naphthoyl)indole).
(XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-naphthoyl)indole).
(XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
(XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-naphthoyl)indole).
(XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-naphthoyl)indole).
(XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
(XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
(XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole).
(XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole).
(XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
(XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-naphthoyl)carbazole).
c. Naphthoylpyrroles.—Any compound containing a naphthoylpyrrole structure, with or without substitution on the pyrrole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to:
(I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
(II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
(III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
(IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
(V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
(VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole).
(VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-naphthoyl)pyrrole).
(VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-naphthoyl)pyrrole).
(IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-naphthoyl)pyrrole).
(X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole).
d. Naphthylmethylenindenes.—Any compound containing a naphthylmethylenindene structure, with or without substitution at the 3-position of the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to, JWH-176 (3-Pentyl-1-(naphthylmethylene)indene).
e. Phenylacetylindoles and Phenylacetylindazoles.—Any compound containing a phenylacetylindole or phenylacetylindazole structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the phenyl ring to any extent, including, but not limited to:
(I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
(II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
(III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
(IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
(V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
(VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
(VII) Cannabipiperidiethanone.
(VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole).
f. Cyclohexylphenols.—Any compound containing a cyclohexylphenol structure, with or without substitution at the 5-position of the phenolic ring to any extent, whether or not substituted on the cyclohexyl ring to any extent, including, but not limited to:
(I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol).
(II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8) homologue).
(III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-methyloctan-2-yl)phenol).
g. Benzoylindoles and Benzoylindazoles.—Any compound containing a benzoylindole or benzoylindazole structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the phenyl ring to any extent, including, but not limited to:
(I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
(II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
(III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodo-5-nitrobenzoyl)indole).
(IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole).
(V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole).
(VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
(VII) RCS-4 C4 homologue (1-Butyl-3-(4-methoxybenzoyl)indole).
(VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-3-(4-methoxybenzoyl)indole).
h. Tetramethylcyclopropanoylindoles and Tetramethylcyclopropanoylindazoles.—Any compound containing a tetramethylcyclopropanoylindole or tetramethylcyclopropanoylindazole structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the tetramethylcyclopropyl group to any extent, including, but not limited to:
(I) UR-144 (1-Pentyl-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indazole).
(IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
(X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole carboxamides, and Adamantylindazole carboxamides.—Any compound containing an adamantoyl indole, adamantoyl indazole, adamantyl indole carboxamide, or adamantyl indazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent, including, but not limited to:
(I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
(II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide).
(III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide).
(IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-adamantoyl)indole).
(V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
(VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
(VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-adamantoyl)indole).
j. Quinolinylindolecarboxylates, Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides, and Quinolinylindazolecarboxamides.—Any compound containing a quinolinylindole carboxylate, quinolinylindazole carboxylate, isoquinolinylindole carboxylate, isoquinolinylindazole carboxylate, quinolinylindole carboxamide, quinolinylindazole carboxamide, isoquinolinylindole carboxamide, or isoquinolinylindazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the quinoline or isoquinoline ring to any extent, including, but not limited to:
(I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
(II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-carboxylate).
(III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-carboxylate).
(IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-carboxylate).
(V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
(VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole-3-carboxylate).
(VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole-3-carboxylate).
(VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
(IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3-carboxamide).
k. Naphthylindolecarboxylates and Naphthylindazolecarboxylates.—Any compound containing a naphthylindole carboxylate or naphthylindazole carboxylate structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to:
(I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-carboxylate).
(II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-carboxylate).
(III) Fluoro SDB-005 (1-Naphthalenyl 1-(fluoropentyl)indazole-3-carboxylate).
(IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-carboxylate).
(V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-carboxylate).
l. Naphthylindole carboxamides and Naphthylindazole carboxamides.—Any compound containing a naphthylindole carboxamide or naphthylindazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to:
(I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
(II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-3-carboxamide).
(III) Chloro-NNEI (N-Naphthalen-1-yl 1-(chloropentyl)indole-3-carboxamide).
(IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-carboxamide).
(V) Fluoro MN-18 (N-Naphthalen-1-yl 1-(fluoropentyl)indazole-3-carboxamide).
m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl indazole carboxamides, Alkylcarbonyl indole carboxylates, and Alkylcarbonyl indazole carboxylates.—Any compound containing an alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an indole carboxamide, indazole carboxamide, indole carboxylate, or indazole carboxylate, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the alkylcarbonyl group to any extent, including, but not limited to:
(I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindole-3-carboxamide).
(II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(fluoropentyl)indole-3-carboxamide).
(III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indole-3-carboxamide).
(IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).
(V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
(VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).
(VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
(VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
(IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
(X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
(XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
(XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
(XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).
(XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
(XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
(XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
(XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
(XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
(XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)indole-3-carboxamide).
(XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide).
(XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
(XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
(XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—Any compound containing a N-(2-phenylpropan-2-yl) indole carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide structure, with or without substitution on the indole or indazole ring to any extent, whether or not substituted on the phenyl ring of the cumyl group to any extent, including, but not limited to:
(I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-carboxamide).
(II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-(fluoropentyl)indole-3-carboxamide).
o. Other Synthetic Cannabinoids.—Any material, compound, mixture, or preparation that contains any quantity of a Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
(I) With or without modification or replacement of a carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage between either two core rings, or linkage between a core ring and group structure, with or without the addition of a carbon or replacement of a carbon;
(II) With or without replacement of a core ring or group structure, whether or not substituted on the ring or group structures to any extent; and
(III) Is a cannabinoid receptor agonist, unless specifically excepted or unless listed in another schedule or contained within a pharmaceutical product approved by the United States Food and Drug Administration.
191. Substituted Cathinones.—Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations:
a. Any compound containing a 2-amino-1-phenyl-1-propanone structure;
b. Any compound containing a 2-amino-1-naphthyl-1-propanone structure; or
c. Any compound containing a 2-amino-1-thiophenyl-1-propanone structure,
whether or not the compound is further modified:
(I) With or without substitution on the ring system to any extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy, haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide substituents;
(II) With or without substitution at the 3-propanone position with an alkyl substituent or removal of the methyl group at the 3-propanone position;
(III) With or without substitution at the 2-amino nitrogen atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or not further substituted in the ring system; or
(IV) With or without inclusion of the 2-amino nitrogen atom in a cyclic structure, including, but not limited to:
(A) Methcathinone.
(B) Ethcathinone.
(C) Methylone (3,4-Methylenedioxymethcathinone).
(D) 2,3-Methylenedioxymethcathinone.
(E) MDPV (3,4-Methylenedioxypyrovalerone).
(F) Methylmethcathinone.
(G) Methoxymethcathinone.
(H) Fluoromethcathinone.
(I) Methylethcathinone.
(J) Butylone (3,4-Methylenedioxy-alpha-methylaminobutyrophenone).
(K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
(L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
(M) Naphyrone (Naphthylpyrovalerone).
(N) Bromomethcathinone.
(O) Buphedrone (alpha-Methylaminobutyrophenone).
(P) Eutylone (3,4-Methylenedioxy-alpha-ethylaminobutyrophenone).
(Q) Dimethylcathinone.
(R) Dimethylmethcathinone.
(S) Pentylone (3,4-Methylenedioxy-alpha-methylaminovalerophenone).
(T) Pentedrone (alpha-Methylaminovalerophenone).
(U) MDPPP (3,4-Methylenedioxy-alpha-pyrrolidinopropiophenone).
(V) MDPBP (3,4-Methylenedioxy-alpha-pyrrolidinobutyrophenone).
(W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
(X) PPP (Pyrrolidinopropiophenone).
(Y) PVP (Pyrrolidinovalerophenone) or (Pyrrolidinopentiophenone).
(Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
(AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
(BB) F-MABP (Fluoromethylaminobutyrophenone).
(CC) Me-EABP (Methylethylaminobutyrophenone).
(DD) PBP (Pyrrolidinobutyrophenone).
(EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
(FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
(GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
(HH) Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
(II) 3,4-Methylenedioxy-N,N-diethylcathinone.
(JJ) 3,4-Methylenedioxy-N-acetylcathinone.
(KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
(LL) 3,4-Methylenedioxy-N-acetylethcathinone.
(MM) Methylbuphedrone (Methyl-alpha-methylaminobutyrophenone).
(NN) Methyl-alpha-methylaminohexanophenone.
(OO) N-Ethyl-N-methylcathinone.
(PP) PHP (Pyrrolidinohexanophenone).
(QQ) PV8 (Pyrrolidinoheptanophenone).
(RR) Chloromethcathinone.
(SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
192. Substituted Phenethylamines.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations, any compound containing a phenethylamine structure, without a beta-keto group, and without a benzyl group attached to the amine group, whether or not the compound is further modified with or without substitution on the phenyl ring to any extent with alkyl, alkylthio, nitro, alkoxy, thio, halide, fused alkylenedioxy, fused furan, fused benzofuran, fused dihydrofuran, or fused tetrahydropyran substituents, whether or not further substituted on a ring to any extent, with or without substitution at the alpha or beta position by any alkyl substituent, with or without substitution at the nitrogen atom, and with or without inclusion of the 2-amino nitrogen atom in a cyclic structure, including, but not limited to:
a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
j. 2C-H (2,5-Dimethoxyphenethylamine).
k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
m. MDMA (3,4-Methylenedioxymethamphetamine).
n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-Methylenedioxy-N-methylbutanamine).
o. MDA (3,4-Methylenedioxyamphetamine).
p. 2,5-Dimethoxyamphetamine.
q. Fluoroamphetamine.
r. Fluoromethamphetamine.
s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
y. PMA (4-Methoxyamphetamine).
z. N-Ethylamphetamine.
aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
cc. PMMA (4-Methoxymethamphetamine).
dd. N,N-Dimethylamphetamine.
ee. 3,4,5-Trimethoxyamphetamine.
ff. 4-APB (4-(2-Aminopropyl)benzofuran).
gg. 5-APB (5-(2-Aminopropyl)benzofuran).
hh. 6-APB (6-(2-Aminopropyl)benzofuran).
ii. 7-APB (7-(2-Aminopropyl)benzofuran).
jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-dihydrobenzofuran),
which does not include phenethylamine, mescaline as described in subparagraph 20., substituted cathinones as described in subparagraph 191., N-Benzyl phenethylamine compounds as described in subparagraph 193., or methamphetamine as described in subparagraph (2)(c)5.
193. N-Benzyl Phenethylamine Compounds.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations, any compound containing a phenethylamine structure without a beta-keto group, with substitution on the nitrogen atom of the amino group with a benzyl substituent, with or without substitution on the phenyl or benzyl ring to any extent with alkyl, alkoxy, thio, alkylthio, halide, fused alkylenedioxy, fused furan, fused benzofuran, or fused tetrahydropyran substituents, whether or not further substituted on a ring to any extent, with or without substitution at the alpha position by any alkyl substituent, including, but not limited to:
a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine).
c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-fluorobenzyl)]phenethylamine).
d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine).
e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine).
g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-fluorobenzyl)]phenethylamine).
h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine).
i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine).
n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-fluorobenzyl)]phenethylamine).
o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine).
p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
q. 25H-NBOH (2,5-Dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine).
r. 25H-NBF (2,5-Dimethoxy-[N-(2-fluorobenzyl)]phenethylamine).
s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine),
which does not include substituted cathinones as described in subparagraph 191.
194. Substituted Tryptamines.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation containing a 2-(1H-indol-3-yl)ethanamine, for example tryptamine, structure with or without mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups, or by inclusion of the amino nitrogen atom in a cyclic structure, whether or not substituted at the alpha position with an alkyl group, whether or not substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups, including, but not limited to:
a. Alpha-Ethyltryptamine.
b. Bufotenine.
c. DET (Diethyltryptamine).
d. DMT (Dimethyltryptamine).
e. MET (N-Methyl-N-ethyltryptamine).
f. DALT (N,N-Diallyltryptamine).
g. EiPT (N-Ethyl-N-isopropyltryptamine).
h. MiPT (N-Methyl-N-isopropyltryptamine).
i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
j. 5-Hydroxy-N-methyltryptamine.
k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
m. Methyltryptamine.
n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
q. DiPT (N,N-Diisopropyltryptamine).
r. DPT (N,N-Dipropyltryptamine).
s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-isopropyltryptamine).
z. Methyl-alpha-ethyltryptamine.
aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
which does not include tryptamine, psilocyn as described in subparagraph 34., or psilocybin as described in subparagraph 33.
195. Substituted Phenylcyclohexylamines.—Unless specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation containing a phenylcyclohexylamine structure, with or without any substitution on the phenyl ring, any substitution on the cyclohexyl ring, any replacement of the phenyl ring with a thiophenyl or benzothiophenyl ring, with or without substitution on the amine with alkyl, dialkyl, or alkoxy substituents, inclusion of the nitrogen in a cyclic structure, or any combination of the above, including, but not limited to:
a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP (Benocyclidine).
b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog of phencyclidine).
c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine analog of phencyclidine).
d. PCPr (Phenylcyclohexylpropylamine).
e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene analog of phencyclidine).
f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
h. Methoxetamine.
i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide.
197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide.
198. AH-7921, 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]-benzamide.
199. U47700, trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide.
200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine, dihydrochloride.
(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including any of its salts, isomers, optical isomers, salts of their isomers, and salts of these optical isomers whenever the existence of such isomers and salts is possible within the specific chemical designation:
1. 1,4-Butanediol.
2. Gamma-butyrolactone (GBL).
3. Gamma-hydroxybutyric acid (GHB).
4. Methaqualone.
5. Mecloqualone.
(2) SCHEDULE II.—A substance in Schedule II has a high potential for abuse and has a currently accepted but severely restricted medical use in treatment in the United States, and abuse of the substance may lead to severe psychological or physical dependence. The following substances are controlled in Schedule II:
(a) Unless specifically excepted or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis:
1. Opium and any salt, compound, derivative, or preparation of opium, except nalmefene or isoquinoline alkaloids of opium, including, but not limited to the following:
a. Raw opium.
b. Opium extracts.
c. Opium fluid extracts.
d. Powdered opium.
e. Granulated opium.
f. Tincture of opium.
g. Codeine.
h. Dihydroetorphine.
i. Ethylmorphine.
j. Etorphine hydrochloride.
k. Hydrocodone and hydrocodone combination products.
l. Hydromorphone.
m. Levo-alphacetylmethadol (also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM).
n. Metopon (methyldihydromorphinone).
o. Morphine.
p. Oripavine.
q. Oxycodone.
r. Oxymorphone.
s. Thebaine.
2. Any salt, compound, derivative, or preparation of a substance which is chemically equivalent to or identical with any of the substances referred to in subparagraph 1., except that these substances shall not include the isoquinoline alkaloids of opium.
3. Any part of the plant of the species Papaver somniferum, L.
4. Cocaine or ecgonine, including any of their stereoisomers, and any salt, compound, derivative, or preparation of cocaine or ecgonine, except that these substances shall not include ioflupane I 123.
(b) Unless specifically excepted or unless listed in another schedule, any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:
1. Alfentanil.
2. Alphaprodine.
3. Anileridine.
4. Bezitramide.
5. Bulk propoxyphene (nondosage forms).
6. Carfentanil.
7. Dihydrocodeine.
8. Diphenoxylate.
9. Fentanyl.
10. Isomethadone.
11. Levomethorphan.
12. Levorphanol.
13. Metazocine.
14. Methadone.
15. Methadone-Intermediate,4-cyano-2-
dimethylamino-4,4-diphenylbutane.
dimethylamino-4,4-diphenylbutane.
16. Moramide-Intermediate,2-methyl-
3-morpholoino-1,1-diphenylpropane-carboxylic acid.
3-morpholoino-1,1-diphenylpropane-carboxylic acid.
17. Nabilone.
18. Pethidine (meperidine).
19. Pethidine-Intermediate-A,4-cyano-1-
methyl-4-phenylpiperidine.
methyl-4-phenylpiperidine.
20. Pethidine-Intermediate-B,ethyl-4-
phenylpiperidine-4-carboxylate.
phenylpiperidine-4-carboxylate.
21. Pethidine-Intermediate-C,1-methyl-4- phenylpiperidine-4-carboxylic acid.
22. Phenazocine.
23. Phencyclidine.
24. 1-Phenylcyclohexylamine.
25. Piminodine.
26. 1-Piperidinocyclohexanecarbonitrile.
27. Racemethorphan.
28. Racemorphan.
29. Remifentanil.
30. Sufentanil.
31. Tapentadol.
32. Thiafentanil.
(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts, isomers, optical isomers, salts of their isomers, and salts of their optical isomers:
1. Amobarbital.
2. Amphetamine.
3. Glutethimide.
4. Lisdexamfetamine.
5. Methamphetamine.
6. Methylphenidate.
7. Pentobarbital.
8. Phenmetrazine.
9. Phenylacetone.
10. Secobarbital.
(d) Dronabinol (synthetic THC) in oral solution in a drug product approved by the United States Food and Drug Administration.
(3) SCHEDULE III.—A substance in Schedule III has a potential for abuse less than the substances contained in Schedules I and II and has a currently accepted medical use in treatment in the United States, and abuse of the substance may lead to moderate or low physical dependence or high psychological dependence or, in the case of anabolic steroids, may lead to physical damage. The following substances are controlled in Schedule III:
(a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant or stimulant effect on the nervous system:
1. Any substance which contains any quantity of a derivative of barbituric acid, including thiobarbituric acid, or any salt of a derivative of barbituric acid or thiobarbituric acid, including, but not limited to, butabarbital and butalbital.
2. Benzphetamine.
3. Buprenorphine.
4. Chlorhexadol.
5. Chlorphentermine.
6. Clortermine.
7. Embutramide.
8. Lysergic acid.
9. Lysergic acid amide.
10. Methyprylon.
11. Perampanel.
12. Phendimetrazine.
13. Sulfondiethylmethane.
14. Sulfonethylmethane.
15. Sulfonmethane.
16. Tiletamine and zolazepam or any salt thereof.
(b) Nalorphine.
(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following controlled substances or any salts thereof:
1. Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
2. Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with recognized therapeutic amounts of one or more active ingredients which are not controlled substances.
3. Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
4. Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with recognized therapeutic amounts of one or more active ingredients that are not controlled substances.
5. Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with recognized therapeutic amounts of one or more active ingredients which are not controlled substances.
6. Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
7. Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with recognized therapeutic amounts of one or more active ingredients which are not controlled substances.
For purposes of charging a person with a violation of s. 893.135 involving any controlled substance described in subparagraph 3. or subparagraph 4., the controlled substance is a Schedule III controlled substance pursuant to this paragraph but the weight of the controlled substance per milliliters or per dosage unit is not relevant to the charging of a violation of s. 893.135. The weight of the controlled substance shall be determined pursuant to s. 893.135(6).
(d) Anabolic steroids.
1. The term “anabolic steroid” means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids, that promotes muscle growth and includes:
a. Androsterone.
b. Androsterone acetate.
c. Boldenone.
d. Boldenone acetate.
e. Boldenone benzoate.
f. Boldenone undecylenate.
g. Chlorotestosterone (Clostebol).
h. Dehydrochlormethyltestosterone.
i. Dihydrotestosterone (Stanolone).
j. Drostanolone.
k. Ethylestrenol.
l. Fluoxymesterone.
m. Formebulone (Formebolone).
n. Mesterolone.
o. Methandrostenolone (Methandienone).
p. Methandranone.
q. Methandriol.
r. Methenolone.
s. Methyltestosterone.
t. Mibolerone.
u. Nortestosterone (Nandrolone).
v. Norethandrolone.
w. Nortestosterone decanoate.
x. Nortestosterone phenylpropionate.
y. Nortestosterone propionate.
z. Oxandrolone.
aa. Oxymesterone.
bb. Oxymetholone.
cc. Stanozolol.
dd. Testolactone.
ee. Testosterone.
ff. Testosterone acetate.
gg. Testosterone benzoate.
hh. Testosterone cypionate.
ii. Testosterone decanoate.
jj. Testosterone enanthate.
kk. Testosterone isocaproate.
ll. Testosterone oleate.
mm. Testosterone phenylpropionate.
nn. Testosterone propionate.
oo. Testosterone undecanoate.
pp. Trenbolone.
qq. Trenbolone acetate.
rr. Any salt, ester, or isomer of a drug or substance described or listed in this subparagraph if that salt, ester, or isomer promotes muscle growth.
2. The term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the United States Secretary of Health and Human Services for such administration. However, any person who prescribes, dispenses, or distributes such a steroid for human use is considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
(e) Ketamine, including any isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
(f) Dronabinol (synthetic THC) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration.
(g) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under s. 505 of the Federal Food, Drug, and Cosmetic Act.
(4) SCHEDULE IV.—
(a) A substance in Schedule IV has a low potential for abuse relative to the substances in Schedule III and has a currently accepted medical use in treatment in the United States, and abuse of the substance may lead to limited physical or psychological dependence relative to the substances in Schedule III.
(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, are controlled in Schedule IV:
1. Alfaxalone.
2. Alprazolam.
3. Barbital.
4. Bromazepam.
5. Butorphanol tartrate.
6. Camazepam.
7. Carisoprodol.
8. Cathine.
9. Chloral betaine.
10. Chloral hydrate.
11. Chlordiazepoxide.
12. Clobazam.
13. Clonazepam.
14. Clorazepate.
15. Clotiazepam.
16. Cloxazolam.
17. Dexfenfluramine.
18. Delorazepam.
19. Dichloralphenazone.
20. Diazepam.
21. Diethylpropion.
22. Eluxadoline.
23. Estazolam.
24. Eszopiclone.
25. Ethchlorvynol.
26. Ethinamate.
27. Ethyl loflazepate.
28. Fencamfamin.
129. Fenfluramine.
30. Fenproporex.
31. Fludiazepam.
32. Flurazepam.
33. Fospropofol.
34. Halazepam.
35. Haloxazolam.
36. Ketazolam.
37. Loprazolam.
38. Lorazepam.
39. Lorcaserin.
40. Lormetazepam.
41. Mazindol.
42. Mebutamate.
43. Medazepam.
44. Mefenorex.
45. Meprobamate.
46. Methohexital.
47. Methylphenobarbital.
48. Midazolam.
49. Modafinil.
50. Nimetazepam.
51. Nitrazepam.
52. Nordiazepam.
53. Oxazepam.
54. Oxazolam.
55. Paraldehyde.
56. Pemoline.
57. Pentazocine.
58. Petrichloral.
59. Phenobarbital.
60. Phentermine.
61. Pinazepam.
62. Pipradrol.
63. Prazepam.
64. Propoxyphene (dosage forms).
65. Propylhexedrine, excluding any patent or proprietary preparation containing propylhexedrine, unless otherwise provided by federal law.
66. Quazepam.
67. Sibutramine.
68. SPA[(-)-1 dimethylamino-1, 2
diphenylethane].
diphenylethane].
69. Suvorexant.
70. Temazepam.
71. Tetrazepam.
72. Tramadol.
73. Triazolam.
74. Zaleplon.
75. Zolpidem.
76. Zopiclone.
77. Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
(5) SCHEDULE V.—A substance, compound, mixture, or preparation of a substance in Schedule V has a low potential for abuse relative to the substances in Schedule IV and has a currently accepted medical use in treatment in the United States, and abuse of such compound, mixture, or preparation may lead to limited physical or psychological dependence relative to the substances in Schedule IV.
(a) Substances controlled in Schedule V include any compound, mixture, or preparation containing any of the following limited quantities of controlled substances, which must include one or more active medicinal ingredients that are not controlled substances in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the controlled substance alone:
1. Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
2. Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
3. Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
4. Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
5. Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
6. Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
(b) Unless a specific exception exists or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is controlled in Schedule V:
1. Brivaracetam.
2. Ezogabine.
3. Lacosamide.
4. Pregabalin.
(c) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: Pyrovalerone.
History.—s. 3, ch. 73-331; s. 247, ch. 77-104; s. 1, ch. 77-174; ss. 1, 2, ch. 78-195; s. 2, ch. 79-325; s. 1, ch. 80-353; s. 1, ch. 82-16; s. 1, ch. 84-89; s. 2, ch. 85-242; s. 1, ch. 86-147; s. 2, ch. 87-243; s. 1, ch. 87-299; s. 1, ch. 88-59; s. 3, ch. 89-281; s. 54, ch. 92-69; s. 1, ch. 93-92; s. 4, ch. 95-415; s. 1, ch. 96-360; ss. 1, 5, ch. 97-1; s. 96, ch. 97-264; s. 1, ch. 99-186; s. 2, ch. 2000-320; s. 1, ch. 2001-55; s. 5, ch. 2001-57; s. 1, ch. 2002-78; s. 2, ch. 2003-10; s. 1, ch. 2008-88; s. 2, ch. 2011-73; s. 1, ch. 2011-90; s. 1, ch. 2012-23; s. 1, ch. 2013-29; s. 1, ch. 2014-159; s. 1, ch. 2015-34; s. 2, ch. 2016-105; s. 4, ch. 2017-107; s. 1, ch. 2017-110; s. 8, ch. 2018-13; s. 2, ch. 2019-166; s. 1, ch. 2021-154; s. 1, ch. 2023-221; s. 1, ch. 2024-20.
1Note.—Section 5, ch. 97-1, repealed paragraph (4)(w) effective upon the removal of fenfluramine from the schedules of controlled substances in 21 C.F.R. s. 1308. Paragraph (4)(w) was redesignated as subparagraph (4)(b)29. by s. 8, ch. 2018-3. The Drug Enforcement Administration, United States Department of Justice, in FR Doc. 2022-27400, filed December 22, 2022, issued a final rule removing fenfluramine from the schedules of the Controlled Substances Act, effective December 23, 2022.
Notes of Decisions
Cited in 280
cases (35 in the last 5 years), 1974–2026 · leading case: In Re Stand. Jury Instructions in Crim. Cases—report No. 2015-03, 191 So. 3d 291 (Fla. 2016).
In Re Stand. Jury Instructions in Crim. Cases—report No. 2015-03, 191 So. 3d 291 (Fla. 2016). “13(6)(b)1Fla: Stat Give if applicable The jury must make a finding as to weight if the defendant is charged with possessing more than 20 grams of cannabis or more than 3 grams of a substance listed in § 893.03(1) (c)i6~_50,. 1U-U2, 151-_ 159, or 166-lW[3_Fla.”
In Re Stand. Jury Instructions in Crim. Cases—report No. 2013-05, 153 So. 3d 192 (Fla. 2014). “-50., 114.-142., 151.-159, or 166.-169., in an amount more than 3 grams, there will be both a felony necessary lesser-ineluded offense of simple possession and a misdemeanor necessary lesser-ineluded offense of simple possession.”
State v. Holland, 689 So. 2d 1268 (Fla. 1st DCA 1997). “Holland was charged with five counts of trafficking in "[h]ydrocodone also known as Lortab and/or Vicodin, a controlled substance defined in Section 893.03 Florida Statutes, in violation of 893.”
In re Stand. Jury Instructions in Crim. Cases-Instructions 25.9-25.13, 112 So. 3d 1211 (Fla. 2013). “Possession of Not More than 20 Grams of Cannabis is a first degree misdemeanor.”
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
In Re: Stand. Jury Instructions in Crim. Cases-Report 2016-09, 216 So. 3d 497 (Fla. 2017). “-l-3^6-X'h-VFlavStatr There is no crime of Attempted Delivery because the definition of “delivery” in § 893.03(6), Fla. Stat. includes the attempt to transfer from one person to another.”
In Re: Stand. Jury Instructions in Crim. Cases-Report 2018-12., 272 So. 3d 243 (Fla. 2019). “There is no crime of Attempted Delivery because the definition of "delivery" in § 893.03(6), Fla. Stat. includes the attempt to transfer from one person to another.”
O'HARA v. State, 964 So. 2d 839 (Fla. 2d DCA 2007). “§ 893.03(2)(a)(1)(j), (3)(c)(3)-(4). Therefore, hydrocodone is a "legend drug" for purposes of section 499.”
Sowell v. State, 738 So. 2d 333 (Fla. 1st DCA 1998). “In so ruling the court accepted the state's assertion that the defense could not be maintained in light of a statutory change pertaining to the medical use of certain controlled substances under section 893.03, Fla. Stat. This statute catalogs various controlled substances…”
State v. Baxley, 684 So. 2d 831 (Fla. 5th DCA 1996). “" But if a tablet contains no more than 15 milligrams of hydrocodone along with other active ingredients which are not controlled substances, then under section 893.03(3)(c)4 such tablet is a SCHEDULE III substance and, under section 893.”
Town v. State Ex Rel. Reno, 377 So. 2d 648 (Fla. 1979). “), which allows cannabis to be used in medical research as the effect of making the classification of cannabis as a Schedule I drug under section 893.03, Florida Statutes (1978 Supp.”
Solomon Chamu v. U.S. Attorney Gen., 23 F.4th 1325 (11th Cir. 2022). “” Fla. Stat. § 893.03 (2)(a)(4) (2003). The federal definition, at least on its face, describes another: cocaine’s “optical and geometric isomers.”
— 893.03(1) — 13 cases
Shelton v. Sec'y, Dep't of Corr., 802 F. Supp. 2d 1289 (M.D. Fla. 2011).
Town v. State Ex Rel. Reno, 377 So. 2d 648 (Fla. 1979). “), which allows cannabis to be used in medical research as the effect of making the classification of cannabis as a Schedule I drug under section 893.03, Florida Statutes (1978 Supp.”
In Re Stand. Jury Instructions in Crim. Cases—report No. 2015-03, 191 So. 3d 291 (Fla. 2016). “13(6)(b)1Fla: Stat Give if applicable The jury must make a finding as to weight if the defendant is charged with possessing more than 20 grams of cannabis or more than 3 grams of a substance listed in § 893.03(1) (c)i6~_50,. 1U-U2, 151-_ 159, or 166-lW[3_Fla.”
Jenks v. State, 582 So. 2d 676 (Fla. 1st DCA 1991).
State v. McCartney, 1 So. 3d 326 (Fla. 4th DCA 2009).
— 893.03(1)(a) — 5 cases
State v. Burch, 545 So. 2d 279 (Fla. 4th DCA 1989).
Albert v. Salce, 439 So. 2d 339 (Fla. 3d DCA 1983).
Sowell v. State, 738 So. 2d 333 (Fla. 1st DCA 1998). “In so ruling the court accepted the state's assertion that the defense could not be maintained in light of a statutory change pertaining to the medical use of certain controlled substances under section 893.03, Fla. Stat. This statute catalogs various controlled substances…”
Rivera v. State of Florida (Fla. 2d DCA 2024).
Thomas Andrew Vana, Jr. v. State of Florida (Fla. 6th DCA 2025).
— 893.03(1)(b) — 4 cases
State v. Holland, 689 So. 2d 1268 (Fla. 1st DCA 1997). “Holland was charged with five counts of trafficking in "[h]ydrocodone also known as Lortab and/or Vicodin, a controlled substance defined in Section 893.03 Florida Statutes, in violation of 893.”
State v. Hayes, 720 So. 2d 1095 (Fla. 4th DCA 1998).
State v. Diloreto, 600 So. 2d 25 (Fla. 4th DCA 1992).
Eagle v. State, 772 So. 2d 1 (Fla. 2d DCA 2000).
— 893.03(1)(b)(11) — 1 case
Williams v. State, 479 So. 2d 878 (Fla. 3d DCA 1985).
— 893.03(1)(c) — 29 cases
Hively v. State, 336 So. 2d 127 (Fla. 4th DCA 1976).
State v. Oliver, 368 So. 2d 1331 (Fla. 3d DCA 1979).
State v. Burch, 545 So. 2d 279 (Fla. 4th DCA 1989).
Young v. State, 439 So. 2d 306 (Fla. 5th DCA 1983).
Bernard Davis v. State of Florida, 244 So. 3d 312 (Fla. 4th DCA 2018).
— 893.03(1)(c)(15) — 1 case
Fiske v. State, 366 So. 2d 423 (Fla. 1978).
— 893.03(1)(c)(190)(a) — 1 case
State of Florida v. Lucas Stevenson (Fla. 4th DCA 2020).
— 893.03(1)(c)(7) — 2 cases
Taylor v. State, 848 So. 2d 1191 (Fla. 5th DCA 2003).
CQ v. State, 801 So. 2d 304 (Fla. 5th DCA 2001).
— 893.03(1)(d) — 2 cases
Sowell v. State, 738 So. 2d 333 (Fla. 1st DCA 1998). “In so ruling the court accepted the state's assertion that the defense could not be maintained in light of a statutory change pertaining to the medical use of certain controlled substances under section 893.03, Fla. Stat. This statute catalogs various controlled substances…”
Dept. of High. Saf. & Mv v. Pollack, 462 So. 2d 1199 (Fla. 3d DCA 1985).
— 893.03(1)(d)(2) — 1 case
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
— 893.03(1)(d)(3) — 2 cases
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
Gray v. State, 915 So. 2d 254 (Fla. 5th DCA 2005).
— 893.03(2) — 9 cases
Foster v. State, 132 So. 3d 40 (Fla. 2013).
Oleckna v. Daytona Disc. Pharmacy, 162 So. 3d 178 (Fla. 5th DCA 2015).
Lennear v. State, 784 So. 2d 1181 (Fla. 5th DCA 2001).
Fink v. Holt, 609 So. 2d 1333 (Fla. 4th DCA 1992).
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
— 893.03(2)(a) — 58 cases
Richards v. State, 37 So. 3d 925 (Fla. 4th DCA 2010).
O'connor v. State, 590 So. 2d 1018 (Fla. 5th DCA 1991).
State v. Holland, 689 So. 2d 1268 (Fla. 1st DCA 1997). “Holland was charged with five counts of trafficking in "[h]ydrocodone also known as Lortab and/or Vicodin, a controlled substance defined in Section 893.03 Florida Statutes, in violation of 893.”
State v. Travis, 808 So. 2d 194 (Fla. 2002).
Dudley v. State, 511 So. 2d 1052 (Fla. 3d DCA 1987).
— 893.03(2)(a)(1) — 1 case
Paey v. State, 943 So. 2d 919 (Fla. 2d DCA 2006).
— 893.03(2)(a)(1)(j) — 1 case
O'HARA v. State, 964 So. 2d 839 (Fla. 2d DCA 2007). “§ 893.03(2)(a)(1)(j), (3)(c)(3)-(4). Therefore, hydrocodone is a "legend drug" for purposes of section 499.”
— 893.03(2)(a)(4) — 19 cases
Lite v. State, 617 So. 2d 1058 (Fla. 1993).
Godfrey v. State, 947 So. 2d 565 (Fla. 1st DCA 2006).
State v. Weller, 590 So. 2d 923 (Fla. 1991).
Shapiro v. State, 390 So. 2d 344 (Fla. 1980).
Bowen v. State, 685 So. 2d 942 (Fla. 5th DCA 1996).
— 893.03(2)(a)(l)(k) — 1 case
Jenkins v. State, 535 So. 2d 352 (Fla. 2d DCA 1988).
— 893.03(2)(a)(l)(o) — 2 cases
Hendley v. State, 58 So. 3d 296 (Fla. 2d DCA 2011).
Mullis v. State, 79 So. 3d 747 (Fla. 2d DCA 2011).
— 893.03(2)(b) — 3 cases
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
State v. McCartney, 1 So. 3d 326 (Fla. 4th DCA 2009).
Rivera v. State of Florida (Fla. 2d DCA 2024).
— 893.03(2)(b)(ll) — 1 case
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
— 893.03(2)(c) — 7 cases
State v. Ashcraft, 378 So. 2d 284 (Fla. 1979).
State v. Vinson, 298 So. 2d 505 (Fla. 2d DCA 1974).
State v. Adams, 600 So. 2d 1302 (Fla. 5th DCA 1992).
City of Tallahassee v. Forfeiture of One Yellow 1979 Fiat 2-Door Sedan Florida Tag No. FVN-467, 414 So. 2d 1100 (Fla. 1st DCA 1982).
Brevard Cnty. Sheriff's Off. v. Brown, 208 So. 3d 1281 (Fla. 5th DCA 2017).
— 893.03(2)(c)(1) — 2 cases
Cohn v. Dept. of Prof'l Reg., 477 So. 2d 1039 (Fla. 3d DCA 1985).
State v. Weeks, 335 So. 2d 274 (Fla. 1976).
— 893.03(2)(c)(2) — 1 case
Denegall v. State, 975 So. 2d 505 (Fla. 2d DCA 2007).
— 893.03(2)(c)(4) — 1 case
Horne v. State, 35 So. 3d 40 (Fla. 2d DCA 2010).
— 893.03(3) — 5 cases
State v. Klayman, 835 So. 2d 248 (Fla. 2002).
City of St. Petersburg v. Austrino, 898 So. 2d 955 (Fla. 2d DCA 2005).
O'HARA v. State, 964 So. 2d 839 (Fla. 2d DCA 2007). “§ 893.03(2)(a)(1)(j), (3)(c)(3)-(4). Therefore, hydrocodone is a "legend drug" for purposes of section 499.”
State v. Hayes, 720 So. 2d 1095 (Fla. 4th DCA 1998).
Hollingshead v. State, 80 So. 3d 424 (Fla. 4th DCA 2012).
— 893.03(3)(a) — 1 case
Hand v. State, 334 So. 2d 601 (Fla. 1976).
— 893.03(3)(a)(6) — 1 case
Cilento v. State, 377 So. 2d 663 (Fla. 1979).
— 893.03(3)(c) — 3 cases
State v. Baxley, 684 So. 2d 831 (Fla. 5th DCA 1996). “" But if a tablet contains no more than 15 milligrams of hydrocodone along with other active ingredients which are not controlled substances, then under section 893.03(3)(c)4 such tablet is a SCHEDULE III substance and, under section 893.”
State v. Holland, 689 So. 2d 1268 (Fla. 1st DCA 1997). “Holland was charged with five counts of trafficking in "[h]ydrocodone also known as Lortab and/or Vicodin, a controlled substance defined in Section 893.03 Florida Statutes, in violation of 893.”
Eagle v. State, 772 So. 2d 1 (Fla. 2d DCA 2000).
— 893.03(3)(c)(4) — 1 case
O'HARA v. State, 964 So. 2d 839 (Fla. 2d DCA 2007). “§ 893.03(2)(a)(1)(j), (3)(c)(3)-(4). Therefore, hydrocodone is a "legend drug" for purposes of section 499.”
— 893.03(3)(d) — 1 case
State v. Holzbacher, 948 So. 2d 935 (Fla. 2d DCA 2007).
— 893.03(3)(e) — 1 case
State v. Boyette, 911 So. 2d 891 (Fla. 1st DCA 2005).
— 893.03(4) — 2 cases
Willis v. State, 320 So. 2d 823 (Fla. 4th DCA 1975).
Shearin v. State, 755 So. 2d 800 (Fla. 2d DCA 2000).
— 893.03(4)(h) — 1 case
In re Forfeiture of a 1977 Datsun 280Z Auto., Vin HLS30408139, 448 So. 2d 78 (Fla. 4th DCA 1984).
— 893.03(4)(o) — 1 case
Whitfield v. State, 620 So. 2d 1027 (Fla. 1st DCA 1993).
— 893.03(4)(p) — 1 case
Carle v. State, 983 So. 2d 693 (Fla. 1st DCA 2008).
— 893.03(4)(q) — 1 case
Fink v. Holt, 609 So. 2d 1333 (Fla. 4th DCA 1992).
— 893.03(4)(r) — 1 case
Fink v. Holt, 609 So. 2d 1333 (Fla. 4th DCA 1992).
— 893.03(6) — 6 cases
In Re Stand. Jury Instructions in Crim. Cases—report No. 2015-03, 191 So. 3d 291 (Fla. 2016). “13(6)(b)1Fla: Stat Give if applicable The jury must make a finding as to weight if the defendant is charged with possessing more than 20 grams of cannabis or more than 3 grams of a substance listed in § 893.03(1) (c)i6~_50,. 1U-U2, 151-_ 159, or 166-lW[3_Fla.”
In Re Stand. Jury Instructions in Crim. Cases—report No. 2013-05, 153 So. 3d 192 (Fla. 2014). “-50., 114.-142., 151.-159, or 166.-169., in an amount more than 3 grams, there will be both a felony necessary lesser-ineluded offense of simple possession and a misdemeanor necessary lesser-ineluded offense of simple possession.”
In re Stand. Jury Instructions in Crim. Cases-Instructions 25.9-25.13, 112 So. 3d 1211 (Fla. 2013). “Possession of Not More than 20 Grams of Cannabis is a first degree misdemeanor.”
In Re: Stand. Jury Instructions in Crim. Cases-Report 2016-09, 216 So. 3d 497 (Fla. 2017). “-l-3^6-X'h-VFlavStatr There is no crime of Attempted Delivery because the definition of “delivery” in § 893.03(6), Fla. Stat. includes the attempt to transfer from one person to another.”
In Re: Stand. Jury Instructions in Crim. Cases-Report 2018-12., 272 So. 3d 243 (Fla. 2019). “There is no crime of Attempted Delivery because the definition of "delivery" in § 893.03(6), Fla. Stat. includes the attempt to transfer from one person to another.”
— 893.03(c) — 1 case
Armstrong v. State, 923 So. 2d 1252 (Fla. 2d DCA 2006).
— 893.03(l)(a) — 2 cases
Harris v. State, 655 So. 2d 1179 (Fla. 1st DCA 1995).
Moore v. State, 172 So. 3d 491 (Fla. 1st DCA 2015).
— 893.03(l)(b) — 1 case
Vasquez v. State, 111 So. 3d 273 (Fla. 2d DCA 2013).
— 893.03(l)(c) — 39 cases
In Re Stand. Jury Instructions in Crim. Cases—report No. 2015-03, 191 So. 3d 291 (Fla. 2016). “13(6)(b)1Fla: Stat Give if applicable The jury must make a finding as to weight if the defendant is charged with possessing more than 20 grams of cannabis or more than 3 grams of a substance listed in § 893.03(1) (c)i6~_50,. 1U-U2, 151-_ 159, or 166-lW[3_Fla.”
In Re Stand. Jury Instructions in Crim. Cases—report No. 2013-05, 153 So. 3d 192 (Fla. 2014). “-50., 114.-142., 151.-159, or 166.-169., in an amount more than 3 grams, there will be both a felony necessary lesser-ineluded offense of simple possession and a misdemeanor necessary lesser-ineluded offense of simple possession.”
Cuva v. State, 687 So. 2d 274 (Fla. 5th DCA 1997).
Parks v. State, 437 So. 2d 790 (Fla. 2d DCA 1983).
Gregory Gun v. State of Florida, 171 So. 3d 184 (Fla. 4th DCA 2015).
— 893.03(l)(c)(10) — 1 case
United States v. Mark Francis Wynn, 544 F.2d 786 (5th Cir. 1977).
— 893.03(l)(c)(7) — 2 cases
J.E. v. Dep't of Child. & Families, 126 So. 3d 424 (Fla. 4th DCA 2013).
C.Q. v. State, 801 So. 2d 304 (Fla. 5th DCA 2001).
— 893.03(l)(d) — 3 cases
Kevin Osorio v. State of Florida, 186 So. 3d 601 (Fla. 4th DCA 2016).
Dugan v. Dugan, 504 So. 2d 1283 (Fla. 1st DCA 1986).
Campbell v. State, 423 So. 2d 608 (Fla. 1st DCA 1982).
— 893.03(l)(d)(2) — 1 case
State v. Quetglas, 901 So. 2d 360 (Fla. 2d DCA 2005). “The trial court’s decision to grant the motion was based on the fact that after Quetglas’s alleged offense the legislature had amended section 893.03 by adding GBL as a specifically named controlled substance in schedule I.”
— 893.03(l)(e) — 1 case
State v. Anthony, 377 So. 2d 1177 (Fla. 1979).
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.